Jim Simons
GLUE icon

Jim Simons’s Monte Rosa Therapeutics GLUE Stock Holding History

Jim Simons’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Sell
102,500
-276,600
-73% -$5.23M ﹤0.01% 1843
2026
Q1 		$6.24M Buy
+379,100
New +$7.25M 0.01% 1235
2025
Q4 		– Sell
-395,733
Closed -$2.93M – 3425
2025
Q3 		$2.93M Sell
395,733
-219,367
-36% -$1.16M ﹤0.01% 1809
2025
Q2 		$2.77M Buy
615,100
+451,000
+275% +$2.01M ﹤0.01% 1906
2025
Q1 		$761K Sell
164,100
-81,600
-33% -$500K ﹤0.01% 2562
2024
Q4 		$1.71M Buy
245,700
+27,000
+12% +$203K ﹤0.01% 2155
2024
Q3 		$1.16M Sell
218,700
-36,014
-14% -$182K ﹤0.01% 2352
2024
Q2 		$953K Buy
254,714
+132,614
+109% +$676K ﹤0.01% 2351
2024
Q1 		$861K Buy
122,100
+16,900
+16% +$100K ﹤0.01% 2572
2023
Q4 		$594K Buy
105,200
+13,700
+15% +$53.7K ﹤0.01% 2709
2023
Q3 		$438K Buy
91,500
+9,700
+12% +$62.4K ﹤0.01% 2769
2023
Q2 		$560K Buy
81,800
+53,900
+193% +$349K ﹤0.01% 2813
2023
Q1 		$217K Buy
27,900
+11,500
+70% +$80K ﹤0.01% 3244
2022
Q4 		$125K Buy
+16,400
New +$137K ﹤0.01% 3559

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Suvretta Capital Management
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jim Simons's GLUE Position: Q2 2026 in Review

Jim Simons reduced its Monte Rosa Therapeutics (GLUE) stake by 73% in Q2 2026, selling an estimated $5.23M and leaving 102,500 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1843.

Jim Simons first reported a position in GLUE in Q4 2022 and has held it in 14 quarters since. The position peaked at $6.24M in Q1 2026. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Jim Simons held 102,500 shares of Monte Rosa Therapeutics worth $2.48M as of Q2 2026.
  • Jim Simons sold 276,600 Monte Rosa Therapeutics shares in Q2 2026, an estimated $5.23M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #1843 holding.
  • Jim Simons first reported a position in Monte Rosa Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Jim Simons's Monte Rosa Therapeutics position peaked at $6.24M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.